研報掘金丨國信證券:維持電投產融“優於大市”評級,靜待資產置換打造A股第三家核電運營商
國信證券研報指出,投資收益減少導致業績同比下降,24年電投產融(000958.SZ)實現歸母淨利潤10.44億元,同比減少17.82%。公司資產置換方案確定,已獲國資委批覆。電投核能控股裝機容量921萬千瓦(含合營),權益裝機745萬千瓦,按照公司5月13日收盤價測算,發行完成後公司市值達到1235.9億元,對應重組完成後公司2023 年業績約爲31.5倍PE。交易完成後,公司將成爲繼中國核電、中國廣核之後A股第三大核電運營商,我國僅有的4張核電運營牌照僅剩華能集團所屬核電資產暫未上市。此外,海陽核電三期獲覈準,集團體內仍有未注入核電資產。維持“優於大市”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.